Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ)
CNY 7.43
(-9.06%)
CNY 7.43
(-9.06%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 847.56 Million CNY | 0.11% |
| 2022 | 846.65 Million CNY | 4.87% |
| 2021 | 807.33 Million CNY | -0.14% |
| 2020 | 808.43 Million CNY | -5.55% |
| 2019 | 855.93 Million CNY | -3.78% |
| 2018 | 889.55 Million CNY | 1.48% |
| 2017 | 876.61 Million CNY | -20.25% |
| 2016 | 1.09 Billion CNY | 4.89% |
| 2015 | 1.04 Billion CNY | 1.23% |
| 2014 | 1.03 Billion CNY | 12.65% |
| 2013 | 919 Million CNY | 192.45% |
| 2012 | 314.24 Million CNY | 2.51% |
| 2011 | 306.54 Million CNY | 1.89% |
| 2010 | 300.87 Million CNY | 18.77% |
| 2009 | 253.32 Million CNY | 7.69% |
| 2008 | 235.24 Million CNY | -4.17% |
| 2007 | 245.47 Million CNY | 104.48% |
| 2006 | 120.05 Million CNY | 31.59% |
| 2005 | 91.22 Million CNY | 26.85% |
| 2004 | 71.91 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 816.04 Million CNY | -3.42% |
| 2024 Q1 | 844.95 Million CNY | -0.31% |
| 2024 Q3 | 796.01 Million CNY | -2.45% |
| 2023 FY | 847.56 Million CNY | 0.11% |
| 2023 Q4 | 847.56 Million CNY | 2.18% |
| 2023 Q1 | 831.19 Million CNY | -1.83% |
| 2023 Q2 | 821.98 Million CNY | -1.11% |
| 2023 Q3 | 829.46 Million CNY | 0.91% |
| 2022 Q2 | 782.74 Million CNY | -0.92% |
| 2022 Q1 | 790.01 Million CNY | -2.15% |
| 2022 Q3 | 806.32 Million CNY | 3.01% |
| 2022 Q4 | 846.65 Million CNY | 5.0% |
| 2022 FY | 846.65 Million CNY | 4.87% |
| 2021 Q4 | 807.33 Million CNY | -2.12% |
| 2021 Q3 | 824.79 Million CNY | 1.67% |
| 2021 Q2 | 811.27 Million CNY | 1.29% |
| 2021 Q1 | 800.96 Million CNY | -0.92% |
| 2021 FY | 807.33 Million CNY | -0.14% |
| 2020 Q4 | 808.43 Million CNY | -3.36% |
| 2020 FY | 808.43 Million CNY | -5.55% |
| 2020 Q1 | 822.18 Million CNY | -3.94% |
| 2020 Q2 | 825.01 Million CNY | 0.34% |
| 2020 Q3 | 836.55 Million CNY | 1.4% |
| 2019 Q1 | 880.25 Million CNY | -1.05% |
| 2019 FY | 855.93 Million CNY | -3.78% |
| 2019 Q3 | 969.8 Million CNY | 0.58% |
| 2019 Q4 | 855.93 Million CNY | -11.74% |
| 2019 Q2 | 964.21 Million CNY | 9.54% |
| 2018 Q3 | 857.04 Million CNY | -1.37% |
| 2018 Q1 | 853.53 Million CNY | -2.63% |
| 2018 FY | 889.55 Million CNY | 1.48% |
| 2018 Q2 | 868.92 Million CNY | 1.8% |
| 2018 Q4 | 889.55 Million CNY | 3.79% |
| 2017 Q3 | 1.08 Billion CNY | -1.31% |
| 2017 Q2 | 1.1 Billion CNY | 1.39% |
| 2017 Q1 | 1.08 Billion CNY | -1.17% |
| 2017 Q4 | 876.61 Million CNY | -19.36% |
| 2017 FY | 876.61 Million CNY | -20.25% |
| 2016 Q3 | 1.05 Billion CNY | 1.87% |
| 2016 Q4 | 1.09 Billion CNY | 4.1% |
| 2016 Q1 | 1.03 Billion CNY | -1.69% |
| 2016 FY | 1.09 Billion CNY | 4.89% |
| 2016 Q2 | 1.03 Billion CNY | 0.61% |
| 2015 Q2 | 1 Billion CNY | -0.47% |
| 2015 FY | 1.04 Billion CNY | 1.23% |
| 2015 Q4 | 1.04 Billion CNY | 4.36% |
| 2015 Q3 | 1 Billion CNY | -0.5% |
| 2015 Q1 | 1.01 Billion CNY | -2.05% |
| 2014 Q2 | 970.35 Million CNY | 2.26% |
| 2014 Q3 | 1.01 Billion CNY | 4.94% |
| 2014 Q4 | 1.03 Billion CNY | 1.67% |
| 2014 Q1 | 948.9 Million CNY | 3.25% |
| 2014 FY | 1.03 Billion CNY | 12.65% |
| 2013 Q3 | 320.71 Million CNY | 7.67% |
| 2013 Q4 | 919 Million CNY | 186.55% |
| 2013 Q1 | 309.34 Million CNY | -1.56% |
| 2013 FY | 919 Million CNY | 192.45% |
| 2013 Q2 | 297.87 Million CNY | -3.71% |
| 2012 Q3 | 308.6 Million CNY | 0.66% |
| 2012 FY | 314.24 Million CNY | 2.51% |
| 2012 Q4 | 314.24 Million CNY | 1.83% |
| 2012 Q2 | 306.56 Million CNY | -0.87% |
| 2012 Q1 | 309.25 Million CNY | 0.88% |
| 2011 Q3 | 306.09 Million CNY | 1.66% |
| 2011 FY | 306.54 Million CNY | 1.89% |
| 2011 Q4 | 306.54 Million CNY | 0.15% |
| 2011 Q1 | 306.47 Million CNY | 1.86% |
| 2011 Q2 | 301.1 Million CNY | -1.75% |
| 2010 Q1 | 257.64 Million CNY | 1.7% |
| 2010 Q4 | 300.87 Million CNY | 4.66% |
| 2010 Q3 | 287.47 Million CNY | -3.36% |
| 2010 Q2 | 297.46 Million CNY | 15.46% |
| 2010 FY | 300.87 Million CNY | 18.77% |
| 2009 Q4 | 253.32 Million CNY | 4.93% |
| 2009 Q3 | 241.42 Million CNY | 1.54% |
| 2009 Q2 | 237.75 Million CNY | 0.99% |
| 2009 Q1 | 235.43 Million CNY | 0.08% |
| 2009 FY | 253.32 Million CNY | 7.69% |
| 2008 FY | 235.24 Million CNY | -4.17% |
| 2008 Q1 | 235.21 Million CNY | -4.18% |
| 2008 Q2 | 226.48 Million CNY | -3.71% |
| 2008 Q3 | 230.24 Million CNY | 1.66% |
| 2008 Q4 | 235.24 Million CNY | 2.17% |
| 2007 Q4 | 245.47 Million CNY | 89.07% |
| 2007 Q2 | 122 Million CNY | 0.0% |
| 2007 FY | 245.47 Million CNY | 104.48% |
| 2007 Q3 | 129.83 Million CNY | 6.42% |
| 2006 FY | 120.05 Million CNY | 31.59% |
| 2006 Q4 | 120.05 Million CNY | 0.0% |
| 2005 FY | 91.22 Million CNY | 26.85% |
| 2004 FY | 71.91 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 13.9 Billion CNY | 93.906% |
| Zhejiang Zhenyuan Share Co., Ltd. | 2.98 Billion CNY | 71.598% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 1.06 Billion CNY | 20.067% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 3.02 Billion CNY | 72.023% |
| Yifan Pharmaceutical Co., Ltd. | 11.49 Billion CNY | 92.63% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 36.52 Billion CNY | 97.679% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | 2.89 Billion CNY | 70.681% |
| Boai NKY Medical Holdings Ltd. | 4.01 Billion CNY | 78.915% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 2.56 Billion CNY | 66.92% |